Moderna shares climbed 3% even after Citigroup downgraded the stock to Sell, citing high valuation following a 222% rise since positive melanoma vaccine trial results. The market seems optimistic about Moderna's personalized cancer vaccine pipeline, especially the upcoming full data expected in late October at a European oncology conference. Citigroup respects the science but warns that the current stock price already reflects the melanoma trial success, limiting further gains without new evidence. Investors will watch for broader cancer treatment potential in the full data to justify Moderna's valuation.
Moderna's market cap stands at $81.23 billion as of Oct 01, 2026 22:11 WIB, with a 1-day gain of 3.00% on Pluang, reflecting continued investor interest despite Citigroup's downgrade. BioNTech trades near $98.12 with a slight dip of 0.18%, while Pfizer holds a strong dividend yield of 6.03% and a market cap of $162.55 billion, showing more stable investor demand. The typical hold time for Moderna on Pluang is 59 days, indicating moderate-term investor confidence amid ongoing developments in its cancer vaccine pipeline.
Citigroup downgraded Moderna from Hold to Sell, citing that the stock's recent surge is not supported by its current cancer vaccine pipeline. Despite a 590% rise in 2026, Citi's analyst raised the price target to $80, still well below Moderna's tradi...
Navitas Semiconductor's shares rose 12% premarket after securing a U.S. Army contract to develop next-generation silicon carbide power semiconductor technology. This project aims to create a domestic manufacturing process for ultra-high-voltage silic...
